scispace - formally typeset
P

Paul J. van Diest

Researcher at Utrecht University

Publications -  514
Citations -  22750

Paul J. van Diest is an academic researcher from Utrecht University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 70, co-authored 459 publications receiving 18892 citations. Previous affiliations of Paul J. van Diest include University Medical Center Utrecht & VU University Medical Center.

Papers
More filters
Journal ArticleDOI

No Amplifications of Hypoxia-Inducible Factor-1α Gene in Invasive Breast Cancer: A Tissue Microarray Study

TL;DR: Increased protein levels of HIF‐1α are not associated with amplification of the HIF-1α gene in human breast cancer, therefore, other mechanisms than gene amplification must be responsible for Hif‐α overexpression at normoxia.
Journal ArticleDOI

Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy.

TL;DR: Results show that these novel microtubule inhibitors have promising anticancer activity and can be potentially used to overcome paclitaxel resistance in the clinical setting.
Journal ArticleDOI

Immunophenotyping invasive breast cancer: paving the road for molecular imaging

TL;DR: 80% of all breast cancers express at least one of a panel of membrane markers (CD44v6, GLUT1, EGFR, HER2, and IGF1-R) that may therefore be suitable for molecular imaging strategies, and this study serves as a starting point for further development of a set of antibody-based optical tracers with a high breast cancer detection rate.
Journal ArticleDOI

Digital pathology in the time of corona.

TL;DR: This paper provides an overview of the way of working during the 2020 COVID-19 crisis with emphasis on the virtues of digital pathology.
Journal ArticleDOI

Fibrotic focus and hypoxia in male breast cancer

TL;DR: The presence of a fibrotic focus is associated with hypoxia-inducible factor-1α overexpression, and both are associated with aggressive tumor phenotype and poor survival in male breast cancer.